A Comprehensive Review of Fear of Eating Behaviour in Individuals with Diabetes: Exploring Therapeutic Interventions for Diabulimia.

Objective: This review aims to comprehensively analyse the fear of eating behaviour in individuals with diabetes, known as diabulimia or ED-DMT1. The emotional and psychological factors contributing to disordered eating behaviours, their impact on diabetes management, and potential consequences on physical health are explored. Various therapeutic interventions, including cognitive-behavioural therapy and psychological support, the role of nutrition education, individualized treatment plans support groups in managing fear of eating behaviour in diabetes are examined and discussed.

Deciphering the mechanisms and effects of hyperglycemia on skeletal muscle atrophy.

Hyperglycemia, a hallmark of diabetes mellitus, significantly contributes to skeletal muscle atrophy, characterized by progressive muscle mass and strength loss. This review summarizes the mechanisms of hyperglycemia-induced muscle atrophy, examines clinical evidence, and discusses preventive and therapeutic strategies. A systematic search of electronic databases, including PubMed, Scopus, and Web of Science, was conducted to identify relevant papers on hyperglycemic skeletal muscle atrophy.

Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance.

Alzheimer's disease (AD) is a leading cause of cognitive decline in the aging population, presenting a critical need for early diagnosis and effective prognostic tools. Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNAs, have emerged as promising biomarkers for AD due to their roles in regulating gene expression and potential for reversibility. This review examines the current landscape of epigenetic biomarkers in AD, emphasizing their diagnostic and prognostic relevance.

AI in Clinical Trials and Drug Development: Challenges and Potential Advancements.

Artificial intelligence (AI) is one of the fastest-growing fields in various industries, including engineering, architecture, medical and clinical research, aerospace, and others. AI, which is a combination of machine learning (ML), deep learning (DL), and human intelligence (HI), is revolutionizing drug discovery and development by making it more cost-effective and efficient. It is also being used in fields such as medicinal chemistry, molecular and cell biology, pharmacology, pharmacokinetics, formulation development, and toxicology.